NEWSpublisher 2007 :: AngloChinese Investments
SEARCH COMPANY
name:
trunover in millions USD:
from:    to: 
R & D turnover in millions USD:
from:     to: 
NET profit:
from:    to: 
employees:
from:    to: 
COMPANIES
APPROVALS
ACTIVITIES ENGAGED IN
R & D
CLINICAL TRIALS
NON CLINICAL & PRECLINICAL
CHEMISTRY-CONTRACT MANUFACTURE
TEST
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY DETAILS » Eisai Co.,Ltd. back to previous page show list

Eisai Co.,Ltd.

»
address: 4-6-10 Koishikawa, Bunkyo-ku,
Tokyo 112-8088,
Japan
contact: TEL:81-3-3817-3700
key person: Haruo Naito, President and CEO

Soichi Matsuno, Deputy President

Hideaki Matsui, Executive Vice President

trunover in millions USD: 5011
R & D turnover in millions USD: 777
NET profit: 528
year of financial results: 2006
employees: 9472

active in China: YES
partner in China: Eisai (China) Co.,Ltd.

SFDA approved: YES
SFDA approved date: 01/11/1998
Address & Contact Details: Eisai (Suzhou) Co,.Ltd.
32 Baiyu Road,
Suzhou Industrial Park,
Jiangsu Province
P.R.China

TEL:0512-67613211

Approvals:
GLP: NO
GMP: YES
AAALAC: NO
SEPA: NO

Activities engaged in:
Manufacture: YES
Active Pharmaceutical: NO
R&D: NO
Ingredients: NO
Western Generics: NO
TCM: NO

R & D:
Discovery: NO
Work Up (pilot to production): NO
Analysis: NO
Quality Control: NO
Stability: NO
Batch Release: NO

Clinical trials:
Run/Manage: NO
Data management: NO
Support Labs: NO

Non clinical & preclinical:
Animal Testing: GLP: NO
New materials Safety Assessment: NO
Pharmaceuticals: NO
Agrochemicals: NO
Industrial & Other Chemicals: NO
Non GLP - Discovery ADME: NO

Chemistry-contract manufacture:
Generics: NO
API: NO
Licensed Drugs: NO

test:
R&D: NO
 

Eisai Co., Ltd. Japan is a multinational pharmaceutical company with strong R&D capabilities. It was founded in 1941, with the headquarters located in Tokyo . Since its foundation, the Company has actively expanded into overseas markets and now has sales subsidiaries and factories in America , Europe and Asia . With Tsukuba Research Laboratories serving as a coordinating center, approximately 1300 researchers globally work around the clock to develop next-generation and innovative new drugs to satisfy unmet medical needs. They focused on areas of expertise in neurology and gastrointestinal diseases, as well as oncology. They are also expanding research into new frontier areas in order to establish future specialty fields.

Eisai China Inc. is a pharmaceutical company solely invested by Eisai Co., Ltd. Japan , a multinational pharmaceutical company. Eisai has been developing smoothly in China since the early 1990s. It went through Shenyang Eisai and Eisai Suzhou successively (a Japan-funded company, located in Suzhou industrial Park), and later it was renamed as Eisai China Inc. since 2002.
 
Eisai China Inc., Suzhou Plant is located in Suzhou Industrial Park. The total investment amounts to USD 50 million. The total area of the company site is 25,000 square meters, of which the first-stage production building occupies 5,000 square meters, the second one 800 square meters, administration block 800 square meters and greenery 15,000 square meters. It was registered in March 1996, and the construction of the factory was finished in June 1998. It received GMP certification in the same years and production officially began in May 1999. The Suzhou Plant has begun a garbage-sorting program. The plant plans to continue its effects in order to become the "Green Eisai" in China.
 
Taking the hhc as corporation commitment, Compliance as business guide, and GMP as quality standard, Eisai China Inc. not only provides high-quality, environment-friendly, safe and satisfied products and services to They will make unceasing efforts in contributing to development of China 's pharmacy market. At present, Neurology, Digestive diseases and cardiovascular disease are major areas on which their products focused.

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.